WeVote
Log In

Bill

Bill

HB 1390

Affordable prescription drugs; create task force to study impact of alternative funding programs on patient access to.

2025 Regular Session Introduced by Angela Cockerham

Mississippi bill proposing task force to study alternative funding programs for prescription drug affordability died in committee without action.

Died In Committee
#publichealthandhumanservices
0
WeVote Research Nonpartisan
Bill Summary · HB 1390

Legislative bill overview

HB 1390 proposed creating a task force in Mississippi to study how alternative funding programs affect patient access to affordable prescription drugs. The bill aimed to investigate mechanisms beyond traditional insurance models that could help patients afford medications. The legislation died in committee on February 4, 2025, without advancing to a floor vote.

Why is this important

Prescription drug costs remain a significant barrier to healthcare access for many Americans, including Mississippians. Understanding alternative funding models—such as patient assistance programs, bulk purchasing initiatives, or subsidized distribution programs—could inform policy decisions that improve medication affordability and adherence. A systematic study could provide evidence-based recommendations for state-level interventions.

Potential points of contention

  • Cost of task force operations: Opponents may question the expense of conducting the study versus directing resources directly to assistance programs
  • Scope and authority limitations: A state task force has limited ability to influence federal drug pricing or pharmaceutical company practices, raising questions about practical implementation of findings
  • Pharmaceutical industry concerns: Drug manufacturers might resist studies that could lead to pricing restrictions or alternative distribution models that reduce their profit margins

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.